Table 2 Clinical trial on brain metastasis based on liquid biopsies

NCT04785521

Blood samples (serum)

BrM from melanoma, lung, and breast cancer treated with stereotactic radiosurgery (SRS)

Recruiting

a) Serum GOT1, GPT, LDH, glutamate, aspartate, and lactate determination and comparison in:

-newly diagnosed BrM patients before SRS treatment.

-melanoma, breast, and lung cancer patients without BrM.

-newly diagnosed BrM and non-BrM patients.

-patients carrying benign intracranial lesions (before and after SRS treatment).

b) Studying correlation of serum markers with MRI changes following SRS treatment.

NCT03550391

Plasma and serum

Patients with BrM (all cancer types)

Recruiting

-Whether detectable somatic mutations from liquid biopsy could be able to predict overall survival of patients with BrM and development of new BrM.

-Analysis of serum biomarkers such as C-reactive proteins and brain-derived neurotrophic factors to elucidate genomic changes or molecular mechanism of neurocognitive decline associated with BrM.

-To compare overall survival in BrM patients who receive SRS treatment to patients who receive hippocampal-avoidant (HA-WBRT) radiotherapy.

NCT04109131 (BrainStorm)

Blood sample (for plasma & serum) CSF

TNBC/HER2+ BC, NSCLC, SCLC, and melanoma

Recruiting

-Epidemiology of CNS metastases and identification of risk factors for CNS metastases (including time to first CNS event and time to second or subsequent CNS events after first treatment).

-Understand heterogeneity between the primary tumor and the CNS metastasis.

-Identification of promising therapeutic targets for novel compounds.

-Building clinico-pathological database for patients with newly diagnosed non-CNS metastatic solid tumors with high risk of developing CNS metastasis.

-ctDNA analysis from CSF samples.

NCT03257735

Blood and CSF

NSCLC

Recruiting

Gene mutation status in CSF, blood, and tissues, and comparison of mutations after first session and during tumor progression to explore the role of liquid biopsy in the diagnosis and therapeutic advancement of NSCLC with BrM.

NCT02058953

Blood and CSF

Melanoma

Completed

To understand if melanoma CNS metastases are similar to primary melanoma, and development of biomarkers for the prediction of CNS metastases from primary melanoma.